Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab + DRd vs DRd in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
NCT06932562Phase 3Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2036
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab in multiple myeloma (MM) (2 arms). Primary endpoints: Minimal Residual Disease at 11 years, Minimal Residual Disease negative Complete Response status by BICR at 11 years and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06932562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932562.